Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

How our clients use DrugPatentWatch

Generated: May 23, 2017

DrugPatentWatch Database Preview

Fludarabine phosphate - Generic Drug Details

« Back to Dashboard

What are the generic drug sources for fludarabine phosphate and what is the scope of fludarabine phosphate patent protection?

Fludarabine phosphate
is the generic ingredient in three branded drugs marketed by Actavis Totowa, Mustafa Nevzat Ilac, Sandoz, Genzyme Corp, Actavis Llc, Fresenius Kabi Usa, Mylan Labs Ltd, Sagent Pharms, Sanofi Aventis Us, and Hospira, and is included in thirteen NDAs. There are three patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Fludarabine phosphate has sixty-four patent family members in thirty-four countries.

There are ten drug master file entries for fludarabine phosphate. Nine suppliers are listed for this compound.

Summary for Generic Name: fludarabine phosphate

Drug Master File Entries: see list10
Suppliers / Packagers: see list9
Bulk Api Vendors: see list48
Clinical Trials: see list742
Patent Applications: see list5,877
Formulation / Manufacturing:see details
Drug Prices:see low prices
DailyMed Link:fludarabine phosphate at DailyMed

Pharmacology for Ingredient: fludarabine phosphate

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Sanofi Aventis Us
fludarabine phosphate
TABLET;ORAL022273-001Dec 18, 2008DISCNNoNo7,148,207► SubscribeY ► Subscribe
fludarabine phosphate
INJECTABLE;INJECTION022137-001Sep 21, 2007APRXYesYes► Subscribe► Subscribe
Fresenius Kabi Usa
fludarabine phosphate
INJECTABLE;INJECTION078393-001Oct 15, 2007APRXNoYes► Subscribe► Subscribe
Mylan Labs Ltd
fludarabine phosphate
INJECTABLE;INJECTION200648-001Oct 16, 2012APRXNoNo► Subscribe► Subscribe
Mustafa Nevzat Ilac
fludarabine phosphate
INJECTABLE;INJECTION090724-001Sep 27, 2010APRXNoNo► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Subscribe for Complete Access

  • Analyze global market entry opportunities
  • Formulary management
  • Set up watchlists for daily email updates

► Plans and Pricing

Expired Orange Book Patents

 Available with subscription

Paragraph IV Activity

 Available with subscription

Patent Maintenance

 Available with subscription

Non-Orange Book Patents

 Available with subscription

International Patents

 Available with subscription

Supplementary Protection Certificates

 Available with subscription

« Back to the Dashboard

For more information try a trial or see the database preview and plans and pricing

How our clients use DrugPatentWatch

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted

Follow DrugPatentWatch:

Google Plus